US 12,275,791 B2
Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
Gregory P. Chang, Medford, MA (US); Ann F. Cheung, Lincoln, MA (US); Daniel Fallon, Winchester, MA (US); Asya Grinberg, Lexington, MA (US); William Haney, Wayland, MA (US); Steven O'Neil, Wayland, MA (US); Nicolai Wagtmann, Concord, MA (US); Ronnie Wei, Weston, MA (US); Bradley M. Lunde, Lebanon, NH (US); and Bianka Prinz, Lebanon, NH (US)
Assigned to Dragonfly Therapeutics, Inc., Waltham, MA (US)
Appl. No. 17/265,876
Filed by Dragonfly Therapeutics, Inc., Waltham, MA (US)
PCT Filed Aug. 7, 2019, PCT No. PCT/US2019/045561
§ 371(c)(1), (2) Date Feb. 4, 2021,
PCT Pub. No. WO2020/033587, PCT Pub. Date Feb. 13, 2020.
Claims priority of provisional application 62/716,259, filed on Aug. 8, 2018.
Prior Publication US 2021/0198369 A1, Jul. 1, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 16/32 (2006.01)
CPC C07K 16/2851 (2013.01) [C07K 16/283 (2013.01); C07K 16/32 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 6 Claims
 
1. A multi-specific binding protein comprising
(a) a Fab that binds NKG2D;
(b) a single-chain variable fragment (scFv) that binds HER2; and
(c) an antibody Fc domain that binds CD16,
wherein the multi-specific binding protein comprises:
a first polypeptide comprising the amino acid sequence of SEQ ID NO: 141;
a second polypeptide comprising the amino acid sequence of SEQ ID NO: 140; and
a third polypeptide comprising the amino acid sequence of SEQ ID NO: 142.